X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.
Lead Product(s): BKV Neutralising Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: AntiBKV
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.
Lead Product(s): BKV Neutralising Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: AntiBKV
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
AntiBKV is a neutralizing antibody which has been indicated for the treatment of BK virus infections and prevention of BK virus associated complications in kidney transplant recipients.
Lead Product(s): BKV Neutralising Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: AntiBKV
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
MTX-005 is a therapeutic antibody candidate that was identified through the screening of a vast number of kidney transplant patients infected with BK virus to find those few with an eradicating antibody response against the virus.
Lead Product(s): MTX-005
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-005
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development.
Lead Product(s): MTX-005
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-005
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swisscanto
Deal Size: $40.2 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 16, 2022
Details:
The project also includes the ability to rapidly develop a combination antibody partner for COVAB 36 targeted against emerging variants through an ultra-fast update process based on Memo Therapeutic AG’s leading antibody discovery platform.
Lead Product(s): Covab 36
Therapeutic Area: Infections and Infectious Diseases Product Name: Covab 36
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swiss Federal Funding
Deal Size: $11.4 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2021
Details:
MTX-COVAB, human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).
Lead Product(s): MTX-COVAB
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Serum Institute of India
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
In the hamster challenge model, even low MTX-COVAB (5 mg/kg preventive; 10 mg/kg therapeutic) protected against weight loss, a key indicator of disease severity.
Lead Product(s): MTX-COVAB
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
The proceeds of the financing will be used primarily to advance development of MTX-COVAB, Memo Therapeutic AG’s lead antibody candidate for the treatment of COVID-19 through to Phase II clinical studies, including production of GMP material.
Lead Product(s): MTX-COVAB
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swisscanto
Deal Size: $15.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
